1
|
Rondeau E, Lafay-Chebassier C, Fauconneau B, Bouquet E, Perault-Pochat MC, Pain S. Le syndrome d’hyperémèse cannabique : une étiologie encore méconnue…. Therapie 2022. [DOI: 10.1016/j.therap.2022.10.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
2
|
Morales-Endamne O, Fauconneau B, Perault-Pochat MC, Pain S. Le protoxyde d’azote : enquête auprès d’étudiants en médecine de Poitiers en 2021. Therapie 2022. [DOI: 10.1016/j.therap.2022.10.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
3
|
Birault F, Le Bonheur L, Langbour N, Clodion S, Jaafari N, Perault-Pochat MC, Thirioux B. Exposure to High Precariousness Prevalence Negatively Impacts Drug Prescriptions of General Practitioners to Precarious and Non-Precarious Populations: A Retrospective Pharmaco-Epidemiological Study. Int J Environ Res Public Health 2022; 19:ijerph19052962. [PMID: 35270655 PMCID: PMC8910740 DOI: 10.3390/ijerph19052962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/28/2022] [Accepted: 03/01/2022] [Indexed: 12/10/2022]
Abstract
(1) Background: Precarious patients are more difficult to care for due to low literacy rates and poor adherence to treatment and hospitalization. These difficulties have detrimental effects on general practitioners (GPs), deteriorating medical communication, advice, diagnoses, and drug prescriptions. To better understand how precariousness affects primary care, we tested whether, among GPs, exposure to high precariousness prevalence more severely impacts drug prescriptions to precarious and non-precarious populations compared to low precariousness prevalence. Materials and methods: This pharmaco-epidemiological study, using linear regression analyses, compared the defined daily dose of 20 drugs prescribed by GPs to precarious and non-precarious patients in four French regions with low and high precariousness prevalence in 2015. (2) Findings: Exposure to high precariousness prevalence significantly impacted the prescriptions of nine medications to precarious patients and two medications to non-precarious patients, and distributed into three interaction patterns. (3) Interpretation: The selective over-prescription of drugs with easy intake modalities to precarious patients probably reflects GPs’ attempts to compensate for poor patient compliance. In contrast, the under-prescription of drugs targeting fungal infections in precarious populations and diabetes and cardiovascular diseases in non-precarious populations was seemingly due to a breakdown of empathy and professional exhaustion, causing medical neglect.
Collapse
Affiliation(s)
- François Birault
- Département de Médecine Générale, Faculté de Médecine et de Pharmacie, Université de Poitiers, F-86000 Poitiers, France;
- Département de Médecine Générale, Maison de Santé Pluriprofessionnelle Universitaire des Couronneries, F-86000 Poitiers, France;
- Correspondence: ; Tel.: +33-549-451-111; Fax: +33-549-455-041
| | - Lakshmipriva Le Bonheur
- Département de Médecine Générale, Faculté de Médecine et de Pharmacie, Université de Poitiers, F-86000 Poitiers, France;
- Département de Médecine Générale, Maison de Santé Pluriprofessionnelle Universitaire des Couronneries, F-86000 Poitiers, France;
| | - Nicolas Langbour
- Centre Hospitalier Henri Laborit, Unité de Recherche Clinique Pierre Deniker, F-86021 Poitiers, France; (N.L.); (N.J.); (B.T.)
- Centre de Recherches sur la Cognition et l’Apprentissage, Centre National de la Recherche Scientifique (CNRS 7295), Université de Poitiers, F-86021 Poitiers, France
| | - Sandivanie Clodion
- Département de Médecine Générale, Maison de Santé Pluriprofessionnelle Universitaire des Couronneries, F-86000 Poitiers, France;
| | - Nematollah Jaafari
- Centre Hospitalier Henri Laborit, Unité de Recherche Clinique Pierre Deniker, F-86021 Poitiers, France; (N.L.); (N.J.); (B.T.)
- Centre de Recherches sur la Cognition et l’Apprentissage, Centre National de la Recherche Scientifique (CNRS 7295), Université de Poitiers, F-86021 Poitiers, France
- Département de Psychiatrie, Faculté de Médecine et de Pharmacie, Université de Poitiers, F-86000 Poitiers, France
| | - Marie-Christine Perault-Pochat
- Laboratoire de Neurosciences Expérimentales et Cliniques, Institut National de la Santé et de la Recherche Médicale (INSERM U 1084), Université de Poitiers, F-86000 Poitiers, France;
- Service de Pharmacologie Clinique et Vigilances, Centre Hospitalo-Universitaire de Poitiers, F-86021 Poitiers, France
- Centre Hospitalo-Universitaire de Poitiers, Institut National de la Santé et de la Recherche Médicale (INSERM CIC1402), Université de Poitiers, F-86021 Poitiers, France
| | - Bérangère Thirioux
- Centre Hospitalier Henri Laborit, Unité de Recherche Clinique Pierre Deniker, F-86021 Poitiers, France; (N.L.); (N.J.); (B.T.)
- Centre de Recherches sur la Cognition et l’Apprentissage, Centre National de la Recherche Scientifique (CNRS 7295), Université de Poitiers, F-86021 Poitiers, France
| |
Collapse
|
4
|
Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. J Immunother Cancer 2020; 8:jitc-2020-001622. [PMID: 33428586 PMCID: PMC7768965 DOI: 10.1136/jitc-2020-001622] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2020] [Indexed: 12/27/2022] Open
Abstract
Background Safety of rechallenge of immune checkpoint inhibitor (ICI) after grade ≥2 immune-related adverse events (irAEs) leading to ICI discontinuation remains unclear. Methods All adverse drug reactions involving at least one ICI reported up to December 31, 2019 were extracted from the French pharmacovigilance database. Patients were included if they experienced at least one grade ≥2 irAE resulting in ICI discontinuation, with subsequent ICI rechallenge. The primary outcome was the recurrence of at least one grade ≥2 irAE in these patients after ICI rechallenge. Results We included 180 patients: 61.1% were men (median age of 66 years), 43.9% had melanoma and 78.9% were receiving anti-programmed cell death 1. First ICI discontinuation was related to 191 irAEs. After ICI rechallenge, 38.9% of the patients experienced at least one grade ≥2 irAE. Among them, 70.0% experienced the same irAE, 25.7% a distinct irAE, and 4.3% both the same and a distinct irAE. Lower recurrence rates of irAEs were associated with rechallenge with the same ICI treatment (p=0.02) or first endocrine irAEs (p=0.003). Gastrointestinal irAEs were more likely to recur (p=0.007). The median duration from ICI discontinuation to rechallenge and the severity of the initial irAE did not predict recurrent irAEs after ICI rechallenge (p=0.53 and p=0.40, respectively). Conclusions In this study, 61.1% of the patients who discontinued ICI treatment for grade ≥2 irAEs experienced no recurrent grade ≥2 irAEs after ICI rechallenge. Although ICI rechallenge appears to be safe under close monitoring, it should always be discussed balancing usefulness of rechallenge, patient comorbidities and risk of recurrence of first irAE(s). Due to inherent bias associated with pharmacovigilance studies, further prospective studies are needed to assess risk factors that may influence patient outcomes after ICI rechallenge.
Collapse
Affiliation(s)
- Marion Allouchery
- Pharmacologie clinique et Vigilances, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Thomas Lombard
- Pharmacie à usage intérieur, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Mickael Martin
- Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.,INSERM U1082, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | - Franck Rouby
- CRPV Marseille Provence Corse, service Hospitalo-Universitaire de Pharmacologie Clinique et Pharmacovigilance, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - Marion Sassier
- Centre Régional de PharmacoVigilance, CHU de Caen, Caen, France.,Département de Pharmacologie, CHU de Caen, Caen, France
| | - Celia Bertin
- Département de Pharmacovigilance, Hôpital Henri Mondor, Creteil, France
| | - Marina Atzenhoffer
- Service Hospitalo-Universitaire de Pharmaco-Toxicologie, Hospices Civils de Lyon, Lyon, France
| | - Ghada Miremont-Salame
- INSERM, BPH, U1219Univ. Bordeaux, INSERM, BPH, U1219, F-33000 Bordeaux, France.,CHU de Bordeaux, Pole de Santé Publique, Pharmacologie Médicale, Centre de Pharmacovigilance de Bordeaux, Bordeaux, France
| | - Marie-Christine Perault-Pochat
- Pharmacologie clinique et Vigilances, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.,Laboratoire de Neurosciences Expérimentales et Cliniques, INSERM U1084, Université de Poitiers, Poitiers, France.,CIC-1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
| | | | | |
Collapse
|
5
|
Abou Taam M, Jacquot B, Ferard C, Thery AC, Mounier C, Grandvuillemin A, Jonville-Béra AP, Perault-Pochat MC. The French pharmacovigilance surveys: A French distinctiveness, a real input. Therapie 2020; 76:441-447. [DOI: 10.1016/j.therap.2020.05.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2020] [Revised: 03/29/2020] [Accepted: 05/19/2020] [Indexed: 11/17/2022]
|
6
|
Barin-Le Guellec C, Lafay-Chebassier C, Ingrand I, Tournamille JF, Boudet A, Lanoue MC, Defossez G, Ingrand P, Perault-Pochat MC, Etienne-Grimaldi MC. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France. Eur J Cancer 2020; 124:37-46. [PMID: 31715555 DOI: 10.1016/j.ejca.2019.09.028] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2019] [Revised: 09/27/2019] [Accepted: 09/30/2019] [Indexed: 12/14/2022]
Abstract
AIMS Despite fluoropyrimidines (FPs) constituting the main component of the chemotherapy combination protocols in 50% of chemotherapies for solid tumour treatments, incidence data for FP-related toxicity are poorly documented in real life. This study evaluated the number of patients receiving FP-based chemotherapies in France, along with the true incidence of FP-related serious adverse effects (SAEs) before the recent mandatory dihydropyrimidine dehydrogenase (DPD)-screening was introduced by French health authorities, DPD being the rate-limiting enzyme of 5-fluorouracil (5-FU) catabolism. METHODS Exhaustive data on the number of patients treated with FP-based chemotherapy in 2013-2014 were collected in the Centre-Val de Loire region of France. True incidence of SAEs was extracted from a cohort of 513 patients with incident solid tumours receiving first-line FP-based chemotherapy. RESULTS After extrapolation at national level, we estimated that 76,200 patients are currently treated annually with 5FU (53,100 patients, 62% digestive system-related versus 26% breast cancers versus 12% head and neck cancers) or capecitabine (23,100 patients, 45% digestive system-related versus 37% breast cancers versus 18% non-documented). Earlier (in the first two cycles) the SAE incidence rate was 19.3% (95% confidence interval (CI) 16-23%) including one toxic death (0.2%, 95%CI 0-1%). SAE incidence rate was 32.2% (95%CI 28-36%) over the first 6 months of treatment. Incidence of death, life-threatening prognosis or incapacity/disability was 1.4% (95%CI 0.4-2.4%) and 1.6% (95%CI 0.5-2.6%) during first two cycles and first 6 months, respectively. CONCLUSION These data highlight the significant public health issue related to FP toxicity, with around 1200 patients developing FP-related life-threatening prognosis or incapacity/disability annually in France, including 150 toxic deaths. It is hoped that DPD-deficiency screening will reduce such iatrogenic events and eradicate toxic deaths.
Collapse
Affiliation(s)
- Chantal Barin-Le Guellec
- Laboratoire de Biochimie et Biologie Moléculaire, Unité de Pharmacogénétique, CHU de Tours, France; INSERM U1248-IPPRIT, Université, CHU de Limoges, France.
| | - Claire Lafay-Chebassier
- Service de Pharmacologie Clinique et Vigilances, Université, CHU de Poitiers, France; INSERM U1084-LNEC/ INSERM CIC 1402, Université, CHU de Poitiers, France
| | - Isabelle Ingrand
- Service de Pharmacologie Clinique et Vigilances, Université, CHU de Poitiers, France; Unité d'Epidémiologie et Biostatistique, Registre Général des Cancers Poitou-Charentes, INSERM CIC 1402, Université, CHU de Poitiers, France
| | | | | | | | - Gautier Defossez
- Unité d'Epidémiologie et Biostatistique, Registre Général des Cancers Poitou-Charentes, INSERM CIC 1402, Université, CHU de Poitiers, France
| | - Pierre Ingrand
- Unité d'Epidémiologie et Biostatistique, Registre Général des Cancers Poitou-Charentes, INSERM CIC 1402, Université, CHU de Poitiers, France
| | - Marie-Christine Perault-Pochat
- Service de Pharmacologie Clinique et Vigilances, Université, CHU de Poitiers, France; INSERM U1084-LNEC/ INSERM CIC 1402, Université, CHU de Poitiers, France
| | | |
Collapse
|
7
|
Vial T, Bailly H, Perault-Pochat MC, Default A, Boulay C, Chouchana L, Kassai B. Beta-lactam-induced severe neutropaenia: a descriptive study. Fundam Clin Pharmacol 2018; 33:225-231. [PMID: 30289173 DOI: 10.1111/fcp.12419] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2018] [Revised: 09/19/2018] [Accepted: 10/01/2018] [Indexed: 12/31/2022]
Abstract
The objectives of this study were to describe the characteristics and natural history of beta-lactam-induced severe neutropaenia and to evaluate the risk of recurrences after another beta-lactam readministration. Reports of pure agranulocytosis associated with a beta-lactam exposure within the 10 days preceding the neutropaenia were extracted from the French Pharmacovigilance Database over the year 2010. Cases with another evident cause or more likely attributable to another drug were excluded. Data were analyzed for demographics, clinical and biological features, prognosis factors, granulocyte colony stimulating factors administration and outcome. Sixty-two cases were included (median age: 65 years). The median duration of treatment before neutropaenia was 16 days. In 47% of cases, the diagnosis was made on a systematic blood cell count. The median neutrophil count at nadir was 0.125 × 109 /L, and bone marrow examination evidenced features of neutrophilic maturation arrest or aplasia in 21 patients, hyperplasia of granulopoietic cells in three and normal findings in five. Three patients developed severe sepsis. All but one recovered a normal blood cell count within 2-56 days after beta-lactam discontinuation. The last patient died from recurrent severe septic shock. No significant effect of granulocyte colony stimulating factor on the mean duration of haematological recovery was found. Among the 21 patients who later received another beta-lactam, two experienced recurrence of the neutropaenia after receiving a beta-lactam from another subfamily. Beta-lactam-induced agranulocytosis was usually observed after prolonged treatment, and severe complications are uncommon. In most patients, a subsequent treatment with another beta-lactam was well tolerated.
Collapse
Affiliation(s)
- Thierry Vial
- Centre Régional de Pharmacovigilance, Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, 162 avenue Lacassagne, Lyon, 69424, France
| | - Henry Bailly
- Centre Régional de Pharmacovigilance, Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, 162 avenue Lacassagne, Lyon, 69424, France
| | | | - Anne Default
- Centre Régional de Pharmacovigilance Marseille - Provence - Corse, Hôpital Sainte-Marguerite AP-HM, 270 boulevard de Saint-Marguerite, 13274, Marseille Cedex 9, France
| | - Charlène Boulay
- Centre Régional de Pharmacovigilance, Institut de Biologie Clinique, Hôpital Charles Nicolle, CHU de Rouen, 76031, Rouen cedex, France
| | - Laurent Chouchana
- Centre Régional de Pharmacovigilance, Hôpitaux Universitaires Paris Centre, Site Hôpital Cochin, 27 rue du faubourg Saint Jacques, 75014, Paris, France
| | - Behrouz Kassai
- Centre Régional de Pharmacovigilance, Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, 162 avenue Lacassagne, Lyon, 69424, France
| | | |
Collapse
|
8
|
Vanderkam P, Gagey S, Ingrand P, Perault-Pochat MC, Brabant Y, Blanchard C, Tudrej B, Messaadi N, Binder P. Are patients' pejorative representations of buprenorphine associated with their level of addiction and of misuse? Drug Alcohol Depend 2018; 188:10-15. [PMID: 29727755 DOI: 10.1016/j.drugalcdep.2018.03.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2017] [Revised: 03/15/2018] [Accepted: 03/16/2018] [Indexed: 10/17/2022]
Abstract
BACKGROUND In France, buprenorphine is at once the most widely prescribed and the most commonly misused opioid maintenance treatment (OMT). Unlike other medicines, it is seldom prescribed as a generic drug. Several studies have underlined the influence of the patient's representations when choosing brand-name rather than generic forms. We aim to prove a link between these pejorative representations and misuse, a higher degree of addiction and a preference for brand-name products. METHODS An observational study carried out at 11 sites in France using self-assessment questionnaires filled out in dispensing pharmacies by patients having come to them for buprenorphine delivery. RESULTS Analysis was based on 806 usable questionnaires. There indeed exists a significant correlation between pejorative representations of OMT by means of buprenorphine, and a higher degree of addiction and misuse (p < .0001 for each). Preference for the brand-name product is correlated with the representation of OMT as a "trap" (p = .020). CONCLUSION Our results underscore the existence of a link between patients' negative representations of their OMT and their drug-taking behavior. Prescribing physicians should consequently take these representations into account to more precisely identify the relevant behaviors and help their patients to evolve positively.
Collapse
Affiliation(s)
- Paul Vanderkam
- Département de Médecine Générale, Faculté de Médecine, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers, France; Unité de recherche clinique intersectorielle en psychiatrie, Centre hospitalier Henri-Laborit, 86021, Poitiers, France.
| | - Stéphanie Gagey
- Département de Médecine Générale, Faculté de Médecine, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers, France
| | - Pierre Ingrand
- Epidémiologie et Biostatistiques, INSERM CIC-1402, Faculté de Médecine, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers, France
| | - Marie-Christine Perault-Pochat
- Pharmacologie Clinique et Vigilance, INSERM CIC-1402, Faculté de Médecine, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers, France
| | - Yann Brabant
- Département de Médecine Générale, Faculté de Médecine, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers, France
| | - Clara Blanchard
- Département de Médecine Générale, Faculté de Médecine, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers, France
| | - Benoit Tudrej
- Département de Médecine Générale, Faculté de Médecine, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers, France
| | - Nassir Messaadi
- Département de Médecine Générale, Faculté de Médecine Lille 2 - Université de Médecine et de Droit, 59045, Lille, France
| | - Philippe Binder
- Département de Médecine Générale, Faculté de Médecine, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers, France
| |
Collapse
|
9
|
Perault-Pochat MC, Laporte S. Introductory letter to the special issue "Country in focus, pharmacology in France". Pharmacol Res 2018; 118:1. [PMID: 28283093 DOI: 10.1016/j.phrs.2017.01.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Marie-Christine Perault-Pochat
- Clinical Pharmacology and Pharmacovigilance INSERM Unit, INSERM U-1084, Clinical and Experimental Neuroscience Laboratory, Poitiers University Hospital, 86021 Poitiers, France
| | - Silvy Laporte
- Dept. of Clinical Pharmacology, University Hospital of Saint-Etienne, INSERM Unit SAINBIOSE U1059, Jean Monnet University and University of Lyon, F-42023 Saint-Etienne, France
| |
Collapse
|
10
|
Quillet A, Colin O, Bourgeois N, Favrelière S, Ferru A, Boinot L, Lafay-Chebassier C, Perault-Pochat MC. Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database. Fundam Clin Pharmacol 2017; 32:227-233. [DOI: 10.1111/fcp.12333] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2017] [Revised: 11/03/2017] [Accepted: 11/09/2017] [Indexed: 02/02/2023]
Affiliation(s)
- Alexandre Quillet
- Service de Pharmacologie Clinique et Vigilances; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
| | - Olivier Colin
- Service de Neurologie; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
| | - Nicolas Bourgeois
- Service de Pharmacologie Clinique et Vigilances; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
| | - Sylvie Favrelière
- Service de Pharmacologie Clinique et Vigilances; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
| | - Aurélie Ferru
- Service d'Oncologie Médicale; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
| | - Laurence Boinot
- Service d'Information Médicale; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
| | - Claire Lafay-Chebassier
- Service de Pharmacologie Clinique et Vigilances; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
| | - Marie-Christine Perault-Pochat
- Service de Pharmacologie Clinique et Vigilances; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
- INSERM, CIC 1402; CHU de Poitiers; 2 rue de la milétrie, 86021 Poitiers France
| |
Collapse
|
11
|
Pain S, Chavant F, Fauconneau B, Guenezan J, Marjanovic N, Lardeur JY, Brunet B, Perault-Pochat MC. Dangerous intoxication after oral ingestion of poppers (alkyl nitrites): Two case reports. Therapie 2016; 72:397-399. [PMID: 27919469 DOI: 10.1016/j.therap.2016.09.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 07/01/2016] [Accepted: 09/23/2016] [Indexed: 10/20/2022]
Affiliation(s)
- Stéphanie Pain
- Centre d'addictovigilance CEIP-A de Poitiers, service de pharmacologie clinique et vigilances, Pavillon R.-Le-Blaye, CHU de Poitiers, rue de la Milétrie, BP 577, 86021 Poitiers, France.
| | - François Chavant
- Centre d'addictovigilance CEIP-A de Poitiers, service de pharmacologie clinique et vigilances, Pavillon R.-Le-Blaye, CHU de Poitiers, rue de la Milétrie, BP 577, 86021 Poitiers, France
| | - Bernard Fauconneau
- Centre d'addictovigilance CEIP-A de Poitiers, service de pharmacologie clinique et vigilances, Pavillon R.-Le-Blaye, CHU de Poitiers, rue de la Milétrie, BP 577, 86021 Poitiers, France
| | - Jérémy Guenezan
- Service urgences-SAMU-SMUR, CHU de Poitiers, 86021 Poitiers, France
| | | | | | - Bertrand Brunet
- Service de toxicologie et pharmacocinétique, CHU de Poitiers, 86021 Poitiers, France
| | - Marie-Christine Perault-Pochat
- Centre d'addictovigilance CEIP-A de Poitiers, service de pharmacologie clinique et vigilances, Pavillon R.-Le-Blaye, CHU de Poitiers, rue de la Milétrie, BP 577, 86021 Poitiers, France
| |
Collapse
|
12
|
Lagarce L, Bernard N, Carlier P, Phelipot-Lates S, Perault-Pochat MC, Drablier G, Bourneau-Martin D, Lainé-Cessac P. Méthotrexate pour grossesse extra-utérine : quels risques en cas de nouvelle grossesse ? Therapie 2016; 71:389-94. [DOI: 10.1016/j.therap.2015.12.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2015] [Accepted: 12/14/2015] [Indexed: 12/27/2022]
|
13
|
Corvol JC, Goni S, Bordet R, Azuar C, Blin O, Checler F, David DJ, Durif F, Fernagut PO, Dupouey J, Otten L, Gaillard R, Kemel ML, Micallef J, Perault-Pochat MC, Pitel AL, Truffinet P. Recherche translationnelle sur les troubles cognitifs et comportementaux dans les maladies neurologiques et psychiatriques. Therapie 2016. [DOI: 10.1016/j.therap.2015.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Binder P, Messaadi N, Perault-Pochat MC, Gagey S, Brabant Y, Ingrand P. Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment. J Addict Dis 2016; 35:101-8. [PMID: 26745033 DOI: 10.1080/10550887.2015.1136494] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
As a form of opioid maintenance treatment, high-dose buprenorphine is increasingly being used in the United States. On the French market since 1996, it is the most commonly prescribed and frequently employed opioid maintenance treatment. For unknown reasons, the brand-name form is used far more often than the generic form (76-24%). The objective was to show that the patients' levels of addiction were differentiated according to the form of buprenorphine currently being used and to their previous experience of a different form. An observational study in 9 sites throughout France used self-assessment questionnaires filled out in retail pharmacies by all patients to whom their prescribed buprenorphine treatment was being delivered. The 151 canvassed pharmacies solicited 879 patients, of whom 724 completed the questionnaires. Participants were statistically similar to non-participants. The patients using the brand-name form subsequent to experience with the generic form exhibited a more elevated addiction severity index and a higher dosage than brand-name form users with no experience of a different form. Compared to generic users, their doses were higher, their was addiction more severe, and their alcohol consumption was more excessive; they were also more likely to make daily use of psychotropic substances. However, the level of misuse or illicit consumption was similar between these groups. Preferring the brand-name buprenorphine form to the generic form is associated with a higher level of severe addiction, a more frequent need for daily psychotropics, and excessive drinking; but the study was unable to show a causal link.
Collapse
Affiliation(s)
- Philippe Binder
- a Department of General Practice , Faculty of Medicine, University of Poitiers , Poitiers , France
| | - Nassir Messaadi
- b Department of General Practice , Faculty of Medicine of Lille 2-University of Health and Law , Lille , France
| | | | - Stéphanie Gagey
- a Department of General Practice , Faculty of Medicine, University of Poitiers , Poitiers , France
| | - Yann Brabant
- a Department of General Practice , Faculty of Medicine, University of Poitiers , Poitiers , France
| | - Pierre Ingrand
- d Department of Epidemiology & Biostatistics , INSERM CIC-1402, Faculty of Medicine , Poitiers , France
| |
Collapse
|
15
|
Linselle M, Montastruc F, Jantzen H, Valnet-Rabier MB, Haramburu F, Coquerel A, Gouraud A, Perault-Pochat MC, Bagheri H, Montastruc JL. Drugs and Sleep Apneas? A review of the French Pharmacovigilance database. Therapie 2015; 70:347-50. [DOI: 10.2515/therapie/2014218] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Accepted: 11/03/2014] [Indexed: 11/20/2022]
|
16
|
Chaboussant PJ, Gagez AL, Graber M, Zhao JM, Chavant F, Perault-Pochat MC, Graber D. Troubles du comportement et hallucinations après consommation d’infusions de feuilles de boldo. Therapie 2014; 69:465-7. [DOI: 10.2515/therapie/2014052] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2014] [Accepted: 04/07/2014] [Indexed: 11/20/2022]
|
17
|
Pain S, Richard G, Chavant F, Remaudière B, Lardeur JY, Fauconneau B, Brunnet B, Mura P, Perault-Pochat MC. Intoxication volontaire aiguë à la trimébutine (Débridat®) : à propos d’un cas avec symptomatologie neurologique type morphinique. Therapie 2013; 68:405-7. [DOI: 10.2515/therapie/2013062] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Accepted: 07/16/2013] [Indexed: 11/20/2022]
|
18
|
Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Castot-Villepelet A, Durrieu G, Gras V, Guy C, Jean-Pastor MJ, Jonville-Béra AP, Merlet-Chicoine I, Miremont-Salamé G, Nourhashemi F, Charmes JP. Adverse drug reactions in patients with Alzheimer's disease and related dementia in France: a national multicentre cross-sectional study. Pharmacoepidemiol Drug Saf 2013; 22:952-60. [PMID: 23794320 DOI: 10.1002/pds.3471] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2013] [Revised: 05/24/2013] [Accepted: 05/27/2013] [Indexed: 11/11/2022]
Abstract
PURPOSE To assess the prevalence of adverse drug reactions (ADRs) occurring in patients with Alzheimer's disease (AD) or other dementia in France. METHODS A cross-sectional multicentre study was conducted by the French network of the 31 regional pharmacovigilance centres on a given day. The subjects were selected by random draw to be a representative sample of French patients with dementia: consultations of dementia clinics, nursing-homes, acute and long care geriatric units, rehabilitation care geriatric units. The staff of each medical structure together with that of the pharmacovigilance centre defined a day for including the patients. Socio-demographic data, history, ADR and drugs given were registered. RESULTS There were 1332 subjects included, 51.1% living at home, 48.8% in institutions, aged 82.0 ± 8.0 years (46-108); 61.3% suffered from AD. Mean number of drugs was 6.3 ± 3.1. Anti-dementia drugs were given to 66.4% subjects. ADR prevalence was 5.0% (95% CI: 3.9-6.2) without a significant difference between at home and institutionalized patients. ADR consisted of gastro-intestinal (23.2%), central nervous system (17.4%) and psychiatric disorders (8.7%). Of the ADR, 31.9% were serious, and 47.8% preventable. The drugs most often involved were anti-dementia (28.9%), cardio-vascular (28.9%) and psychotropic drugs (26.4%, anxiolytics, hypnotics, antidepressants, neuroleptics). CONCLUSION This national scale study showed that iatrogenesis in patients with AD and related dementia can at times be serious and preventable. Therefore, special attention is required when prescribing psychotropic and anti-dementia drugs, as they are frequently used and induce half of the ADR in this population.
Collapse
Affiliation(s)
- Marie-Laure Laroche
- Regional Centre of Pharmacovigilance, Pharmacology-Toxicology-Pharmacovigilance Unit, University Hospital, Limoges, 87042, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Durrieu G, Caillet C, Lacroix I, Jacquet A, Faucher A, Ouaret S, Sommet A, Perault-Pochat MC, Kreft-Jaïs C, Castot A, Damase-Michel C, Montastruc JL. Campagne nationale de vaccination contre la grippe A (H1N1)v : suivi national de pharmacovigilance. Therapie 2011; 66:527-40. [DOI: 10.2515/therapie/2011075] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2010] [Accepted: 07/06/2011] [Indexed: 11/20/2022]
|
20
|
Montastruc G, Favreliere S, Sommet A, Pathak A, Lapeyre-Mestre M, Perault-Pochat MC, Montastruc JL. Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database. Br J Clin Pharmacol 2010; 69:287-94. [PMID: 20233200 DOI: 10.1111/j.1365-2125.2009.03596.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
AIMS To evaluate putative associations between drugs and dilated cardiomyopathy. METHODS We used the case/noncase method in the French PharmacoVigilance Database (FPVD). Cases were all the observations with dilated cardiomyopathy registered into the FPVD between 1 January 1990 and 30 June 2007. Noncases were all other reports other than those studied. Anthracyclines were used as positive controls. Data were expressed as reporting odds ratio (ROR) with their 95% confidence intervals. RESULTS Out of the 258 729 adverse drug reaction (ADR) reports recorded in the FPVD between 1 January 1990 and 30 June 2007, 47 (22 men, mean age 49 years) were defined as dilated cardiomyopathy. In these 47 patients, 67 drugs were 'suspect'. A significant ROR was found with cytotoxic (epirubicin, mitoxantrone, cyclophosphamide, gemcitabine, fluorouracil) and antiretroviral (lamividune, zidovudine, abacavir) but also with isotretinoin, prednisone, appetite suppressant (clobenzorex) and psychotropic [antipsychotic (clozapine, olanzapine), lithium, antidepressant (clomipramine, amitriptyline, fluvoxamine)] drugs. CONCLUSIONS The present study describes an association between some drugs and reports of dilated cardiomyopathies. This relationship involves not only some already suspected drugs (anthracyclines, antiretrovirals), but also other drugs (antipsychotics, lithium, antidepressants, retinoids) less known to induce such an ADR. Despite the mandatory limits of this kind of study (underreporting, confounding factors . . .), these data represent a pharmacovigilance signal and could contribute to establish further prospective studies in order to confirm such signals.
Collapse
|
21
|
|
22
|
Deguil J, Perault-Pochat MC, Chavant F, Lafay-Chebassier C, Fauconneau B, Pain S. Activation of the protein p7OS6K via ERK phosphorylation by cholinergic muscarinic receptors stimulation in human neuroblastoma cells and in mice brain. Toxicol Lett 2008; 182:91-6. [PMID: 18809477 DOI: 10.1016/j.toxlet.2008.08.012] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2008] [Revised: 08/14/2008] [Accepted: 08/26/2008] [Indexed: 11/24/2022]
Abstract
Stimulation of cholinergic muscarinic receptors has been shown to provide substantial protection from DNA damage, oxidative stress and mitochondrial impairment, insults that may be encountered by neurons in development, aging, or neurodegenerative diseases. A study recently indicated that the activation of muscarinic receptors in astrocytoma cells modified the expression of the kinase p70S6K involved in the translational control. The translational control is in part regulated by a cascade of phosphorylation affecting proteins of the anti-apoptotic way controlled by mTOR (mammalian target of rapamycin) and the pro-apoptotic way controlled by PKR. The aim of our study was to investigate the effect of cholinergic muscarinic stimulation by an agonist oxotremorine on the anti-apoptotic way of translational control, in human neuroblastoma cells and in mice brain. Our results showed that muscarinic receptor activation significantly increased the expression of phosphorylated p70S6K, eIF4E and ERK without modification of mTOR activity in neuroblastoma cells and in cerebral cortex and hippocampus of mice, suggesting a stimulation of protein synthesis. Our findings support the notion that synaptic activity, through activation of neurotransmitter receptors, can provide substantial support of cellular survival mechanisms and suggest that loss of such synaptic input increases vulnerability to insult-induced programmed cell death.
Collapse
Affiliation(s)
- Julie Deguil
- University of Poitiers, Research Group on Brain Aging (EA 3808), Pôle de Biologie Santé, 40 avenue du Recteur Pineau, 86022 Poitiers Cedex, France
| | | | | | | | | | | |
Collapse
|
23
|
Chavant F, Lafay-Chebassier C, Al Khidir F, Beauchant M, Perault-Pochat MC. Drug-Induced Hepatitis Due to Doxycycline: A Case Report. Drug Saf 2007. [DOI: 10.2165/00002018-200730100-00099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
24
|
Lafay-Chebassier C, Godeneche G, Descriaud A, Neau JP, Perault-Pochat MC. Mammary Hypertrophy and Depression Induced by Oxetorone: Two Case Reports. Drug Saf 2007. [DOI: 10.2165/00002018-200730100-00126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
25
|
Krupka E, Gendre D, Lafay C, Le Dez O, Gelineau P, Perault-Pochat MC. [Perception of written and oral information by 50 healthy volunteers from a monocentric study]. Therapie 2005; 60:31-8. [PMID: 15929471 DOI: 10.2515/therapie:2005004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The purpose of this survey in 50 healthy volunteers from a single-centre study was to assess from a questionnaire filled in by the participants, their comprehension and evaluation of the written and oral information and the legal framework, as well as their uncertainty regarding participation, in terms of age, gender and profession. Overall satisfaction with regard to comprehension and oral information was recorded, but 42% of volunteers considered the informed consent form too long and one-quarter of them did not read it completely. Knowledge of the legal framework (20%) did not influence either their understanding or hesitation to participate. The hesitant individuals (26%) more often judged this framework to be reassuring than the non-hesitant individuals (77% versus 38%; p = 0.015). These findings concerned females, medics or paramedics and younger individuals (< or =35 years). In individuals who do not give their consent, it would be interesting to study the reasons for refusal to participate and the influence of the ethical and legal framework in clinical trials in enhancing the patients' partnership in a context of evidence-based medicine.
Collapse
Affiliation(s)
- Emmanuel Krupka
- Centre de Recherche Clinique, Service de Pharmacologie Clinique Camille Guérin, CHU La Milétrie, Poitiers, France.
| | | | | | | | | | | |
Collapse
|
26
|
Lardeur JY, Remblier C, Viel S, Raud-Raynier P, Sosner P, Walter M, Baudier D, Perault-Pochat MC. [Myocardial infarct with protease inhibitors: a case report]. Therapie 2002; 57:311-3. [PMID: 12422549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
|
27
|
Cracowski JL, Perault-Pochat MC, Stanke-Labesque F, Vandel B, Bessard G. Using a WWW-based module for problem-based learning in a cardiovascular pharmacology course. Acad Med 2001; 76:394. [PMID: 11299159 DOI: 10.1097/00001888-200104000-00022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
The authors have constructed a problem-based learning (PBL) computer program that makes full use of Internet facilities, and is aimed at providing a stimulating supplement to standard teaching practices. The authors report on students' reactions to this new method of teaching.
Collapse
Affiliation(s)
- J L Cracowski
- Laboratory of Pharmacology, University of Grenoble School of Medicine (UGSM), Grenoble, France
| | | | | | | | | |
Collapse
|